STEM: A Multicentre Phase 2 Study of SFX-01 Treatment and Evaluation in Patients With Estrogen Receptor (ER) Positive and Human Epidermal Growth Factor Receptor 2 (HER2) Negative Metastatic Breast Cancer Progressing on Either an Aromatase Inhibitor (AI) or Tamoxifen or Fulvestrant
Phase of Trial: Phase II
Latest Information Update: 22 Dec 2017
At a glance
- Drugs Aromatase inhibitors (Primary) ; Fulvestrant (Primary) ; Sulforafan (Primary) ; Tamoxifen (Primary)
- Indications Breast cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms STEM
- Sponsors Evgen Pharma
- 22 Dec 2017 Last checked against ClinicalTrials.gov record.
- 23 Nov 2017 Planned End Date changed from 1 Oct 2018 to 1 Dec 2018.
- 23 Nov 2017 Planned primary completion date changed from 1 Feb 2018 to 1 Nov 2018.